Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554996 | 1.00 | PLA2G10 (0.39) | PLA2G10PLA2G5DDB1CRBNELANE | |
| SCHEMBL1555754 | 0.92 | PLA2G10 (0.40) | PLA2G10PLA2G5DDB1CRBNELANE | |
| SCHEMBL1556365 | 0.92 | PLA2G10 (0.40) | PLA2G10PLA2G5DDB1CRBNELANE | |
| SCHEMBL28055093 | 0.85 | PLA2G10 (0.42) | PLA2G10PLA2G5ATM | |
| SCHEMBL28055137 | 0.82 | PLA2G10 (0.42) | PLA2G10PLA2G5 | |
| SCHEMBL27894045 | 0.78 | PLA2G10 (0.43) | PLA2G10PLA2G5ELANEATM | |
| SCHEMBL26427961 | 0.78 | PLA2G10 (0.33) | PLA2G10PLA2G5DDB1CRBNATM | |
| SCHEMBL1344018 | 0.76 | ATM (0.38) | ATM | |
| SCHEMBL1344021 | 0.76 | ATM (0.38) | ATM | |
| SCHEMBL1344136 | 0.76 | ATM (0.38) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8445674-B2 | Heterocyclyl compounds | Hoffmann-La Roche Inc (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR1 | PLA2G10 1675/4885PLA2G5 1867/4885DDB1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.